Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: Validation of utility as a clinical marker

Annals of Surgery

Volumn 227, Issue 3, 1998, Pages 398-404

  Goydos, James S ^a   Brumfield, Anne M ^a   Frezza, Eldo ^a   Booth, Alexandra ^a   Lotze, Michael T ^a,b   Carty, Sally E ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTROPHIN 1; CILIARY NEUROTROPHIC FACTOR; CYTOKINE; INTERLEUKIN 11; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; TUMOR MARKER;

ACUTE PHASE RESPONSE; ARTICLE; BILE DUCT CARCINOMA; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; MEDIATOR RELEASE; MEGAKARYOPOIESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; INTERLEUKIN-6; MALE; TUMOR MARKERS, BIOLOGICAL;

EID: 0031912084     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199803000-00012     Document Type: Article

References (58)

1. Lotz M. Interleukin-6. Cancer Invest 1993; 11(6):732-742.
2. Bazan JF. A novel family of growth factor receptors: A common binding domain in the growth hormone prolactin, erythropoietin and IL-6 receptors and the p75 IL-2 receptor β-chain. Biochem Biophys Res Commun 1989; 164(2):788-795.
3. Nishimoto N, Ogata A, Shima Y, et al. Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer GP130. J Exp Med 1994; 179:1343-1347.
4. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-342.
5. Ohzato H, Yoshizaki K, Nishimoto N, et al. Interleukin-6 as a new indicator of inflammatory status: Detection of serum levels of interleukin-6 and C-reactive protein after surgery. Surgery 1992; 111:201-209.
6. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992; 70(3):709-713.
7. Riche F, Dosquet C, Panis Y, et al. Levels of portal and systemic blood cytokines after colectomy in patients with carcinoma or Crohn's disease. J Am Coll Surg 1995; 180:718-724.
8. Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215: 356-362.
9. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778.
10. Drost AC, Burleson DG, Cioffi WG, et al. Plasma cytokines after thermal injury and their relationship to infection. Ann Surg 1993; 218:74-78.
11. Roumen RMH, Hendriks T, van der Ven-Jongekrijg J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma: Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993; 218: 769-776.
12. Hyams JS, Fitzgerald JE, Treem WR, et al. Relationship of functional and antigenic interleukin-6 to disease activity in inflammatory bowel disease. Gastroenterology 1993; 104:1285.
13. Yoshida Y, Iwaki Y, Pham S, et al. Benefits of posttransplantation monitoring of interleukin-6 in lung transplantation. Ann Thorac Surg 1993; 55:89-93.
14. Jablons DM, McIntosh JK, Mule JJ, et al. Induction of interferon/interleukin-6 by cytokine administration and detection of circulating interleukin-6 in the tumor-bearing state. Ann NY Acad Sci 1989; 557:157-161.
15. Tritarelli E, Rocca E, Testa U, et al. Adoptive immunotherapy with high-dose interleukin-2: Kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level. Blood 1991; 77:741-749.
16. Dosquet C, Schaetz A, Faucher C, et al. Tumor necrosis factor-α, interleukin-1 β, and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994; 30A:162-167.
17. Gallo O, Gori AM, Attanasio M, et al. Interleukin-6 serum level and monocyte production in head and neck cancer. Br J Cancer 1992; 65:479-480.
18. Fearon KCH, McMillan DC, Preston T, et al. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991; 213:26-31.
19. Falconer JS, Fearon KCH, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219:325-331.
20. Plante M, Rubin SC, Wong GY, et al. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73:1882-1888.
21. Blay J-Y, Negrier S, Combaret V, et al. Serum level of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 1992; 52:3317-3322.
22. Stadler WM, Richards JM, Voglezang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: Correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992; 23:1835-1836.
23. Deehan DJ, Heys SD, Simpson WG, et al. In vivo cytokine production and recombinant interleukin-2 immunotherapy: An insight into the possible mechanisms underlying clinical responses. Br J Cancer 1994; 69:1130-1135.
24. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin-6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69:5:911-913.
25. McIntosh JK, Jablons DM, Mule JJ, et al. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol 1989; 143:162-167.
26. Utsumi K, Takai Y, Tada T, et al. Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production. J Immunol 1990; 145:397-403.
27. Matsumoto K, Fujii H, Michalopoulos G, et al. Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: IL-6, HGF and EGF promote DNA synthesis vitro. Hepatology 1994; 20(2):376-382.
28. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993; 126:1299-1304.
29. Cavaillon J-M, Poignet J-L, Fitting C, Delons S. Serum interleukin-6 in long-term hemodialyzed patients. Nephron 1992; 60:307-313.
30. Aarden LA. Hybridoma growth factor. Ann NY Acad Sci 1989; 557:192-199.
31. Shimizu Y, Demetris AJ, Gollin SM, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 1992; 52:252-260.
32. Storto PD, Saidman SL, Demetris AJ, et al. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromos Cancer 1990; 2:300-310.
33. Schoenthaler R, Phillips TL, Castro J, et al. Carcinoma of the extra-hepatic bile ducts: The University of California at San Francisco experience. Ann Surg 1994; 219:267-274.
34. Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995; 130:270-276.
35. Nichols JC, Gores GJ, LaRusso NF, et al. Predicting cholangiocarcinoma in patients with primary sclerosing cholangitis: An analysis of the serological marker CA 19-9. Hepatology 1994; 19:543-545.
36. Curley SA, Izzo F, Gallipoli A, et al. Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg 1995; 222:375-383.
37. Matsuguchi I, Okamura S, Kawasaki C, Niho Y. Production of interleukin-6 from human liver cell lines: Production of interleukin-6 is not concurrent with the production of α-fetoprotein. Cancer Res 1990; 50:7457-7459.
38. Saitoh S, Ikeda K, Koida I, et al. Serum des-gamma-carboxyprothrombin concentration determined by the avidin-biotin complex method in small hepatocellular carcinomas. Cancer 1994; 74:11:2918-2923.
39. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270:943-988.
40. Ullmann CD, Schlom J, Greiner JW. Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. J Immunol 1992; 12:231-241.
41. Weber J, Gunn H, Yang J, et al. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunol 1994; 15:292-302.
42. Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 1993; 53:2118-2122.
43. Goydos JS, Whiteside TL, Finn OJ, Lotze MT. A phase I trial of a synthetic mucin peptide vaccine: Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63:298-304.
44. May LT, Viguet H, Kenney JS, et al. High levels of complexed interleukin-6 in human blood. J Biol Chem 1992; 267:19698-19704.
45. Bemelmans MHA, Gouma DJ, Greve JW, Buurman WA. Cytokines, tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 1992; 15:1132-1136.
46. Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992; 51:1953-1956.
47. Takeda K, Fujii N, Nitta Y, et al. Murine tumor cells metastasizing selectively in the liver: Ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 1991; 82:1299-1308.
48. Lu C, Kerbel RS. Interleukin-6: A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proceedings of the Annual Meeting of the American Association for Cancer Research 1992; 33:A317.
49. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989; 135:427-433.
50. Armstrong CA, Murray N, Kennedy M, et al. Melanoma-derived interleukin-6 inhibits in vivo melanoma growth. J Invest Dermatol 1994; 102:278-284.
51. Kitahara M, Kishimoto S, Hirano T, et al. The in vivo anti-tumor effect of human recombinant interleukin-6. Jpn J Cancer Res 1990; 81:1032-1038.
52. Katz A, Shulman LM, Porgador A, et al. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy. J Imnuinol 1993; 13:98-109.
53. Rabau M, Kashtan H, Baron S, et al. Inhibition of CT-26 murine adenocarcinoma growth in the rectum of mice treated with recombinant human interleukin-6. J Immunol 1994; 15:257-264.
54. Porgador A, Tzehoval E, Katz A, et al. Interleukin-6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52:3679-3686.
55. Mullen CA, Coale MM, Levy AT, et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 1992; 52: 6020-6024.
56. Siegall CB, Kreitman RJ, FitzGerald DJ, Pastan I. Antitumor effects of interleukin-6 Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma PLC/PRF/5 in mice. Cancer Res 1991; 51:2831-2836.
57. Ohe Y, Podack ER, Olsen KJ, et al. Interleukin-6 CDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngenic mice. Br J Cancer 1993; 67:939-944.
58. Halimi H, Eisenstein M, Oh J-W, et al. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells Eur Cytokine Netw 1995; 6:135-143.